Cardiovascular and upper gastrointestinal bleeding consequences of low-dose acetylsalicylic acid discontinuation

Thrombosis and Haemostasis

Volumn 110, Issue 6, 2013, Pages 1298-1304

  Soriano, Lucía Cea ^a   Bueno, Héctor ^b   Lanas, Angel ^c,d   Rodríguez, Luis A García ^a  

^a Department of Pharmacoepidemiology   (Spain)

^b HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^c UNIVERSITY OF ZARAGOZA   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

Aspirin; Cardiovascular; Gastrointestinal haemorrhage; Medication adherence; Primary health care

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; WARFARIN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CASE CONTROL STUDY; CEREBROVASCULAR DISEASE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HEALTH CARE COST; HEART ATRIUM FIBRILLATION; HEART DEATH; HEART INFARCTION; HUMAN; INCIDENCE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; RISK FACTOR; SENSITIVITY ANALYSIS; TRANSIENT ISCHEMIC ATTACK; TREATMENT WITHDRAWAL; UPPER GASTROINTESTINAL BLEEDING;

ASPIRIN; CARDIOVASCULAR; GASTROINTESTINAL HAEMORRHAGE; MEDICATION ADHERENCE; PRIMARY HEALTH CARE;

AGED; AGED, 80 AND OVER; ASPIRIN; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; GASTROINTESTINAL HEMORRHAGE; GREAT BRITAIN; HEALTH CARE COSTS; HUMANS; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; RISK ASSESSMENT; WITHHOLDING TREATMENT;

EID: 84888409379     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH13-04-0326     Document Type: Article

References (38)

1. Martín-Merino E, Johansson S, Bueno H, et al. Discontinuation of low-dose acetylsalicylic acid therapy in UK primary care: incidence and predictors in patients with cardiovascular disease. Prag Obs Res 2012; 3: 1-9.
2. Herlitz J, Toth PP, Naesdal J. Low-dose aspirin therapy for cardiovascular prevention: quantification and consequences of poor compliance or discontinuation. Am J Cardiovasc Drugs 2010; 10: 125-141.
3. García Rodriguez LA, Cea-Soriano L, Martin-Merino E, et al. Discontinuation of low dose aspirin and risk of myocardial infarction: case-control study in UK primary care. Br Med J 2011; 343: d4094.
4. García Rodríguez LA, Cea Soriano L, Hill C, et al. Increased risk of stroke after discontinuation of acetylsalicylic acid: a UK primary care study. Neurology 2011; 76: 740-746.
5. Biondi-Zoccai GG, Lotrionte M, Agostoni P, et al. A systematic review and meta-analysis on the hazards of discontinuing or not adhering to aspirin among 50, 279 patients at risk for coronary artery disease. Eur Heart J 2006; 27: 2667-2674.
6. Maulaz AB, Bezerra DC, Michel P, et al. Effect of discontinuing aspirin therapy on the risk of brain ischemic stroke. Arch Neurol 2005; 62: 1217-1220.
7. Sibon I, Orgogozo JM. Antiplatelet drug discontinuation is a risk factor for ischemic stroke. Neurology 2004; 62: 1187-1189.
8. Lotrionte M, Biondi-Zoccai GG. The hazards of discontinuing acetylsalicylic acid therapy in those at risk of coronary artery disease. Curr Opin Cardiol 2008; 23: 487-493.
9. Cea Soriano L, García Rodríguez LA. Risk of upper gastrointestinal bleeding in a cohort of new users of low-dose ASA for secondary prevention of cardiovascular outcomes. Front Pharmacol 2010; 1: 126-135.
10. O'Neil M, Payne C, Read J. Read Codes Version 3: a user led terminology. Methods Inf Med 1995; 34: 187-192.
11. Lewis JD, Schinnar R, Bilker WB, et al. Validation studies of the health improvement network (THIN) database for pharmacoepidemiology research. Pharmacoepidemiol Drug Saf 2007; 16: 393-401.
12. Pearce N. What does the odds ratio estimate in a case-control study? Int J Epidemiol 1993; 22: 1189-1192.
13. Office for National Statistics. 2010. Population Estimates for UK, England and Wales, Scotland and Northern Ireland, mid 2009. http://www. ons. gov. uk/ons/publications/re-reference-tables. html?edition=tcm%3A77-213645(16/07/2012).
14. Greenhalgh JB, Boland A, Martin Saborido A, et al. Clopidogrel and modifiedrelease dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis. Health Technol Assess 2011; 15: 1366-5278.
15. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy-I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Br Med J 1994; 308: 81-106.
16. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. Br Med J 2002; 324: 71-86.
17. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009; 373: 1849-1860.
18. Björklund L, Wallander MA, Johansson S, et al. Aspirin in cardiology-benefits and risks. Int J Clin Pract 2009; 63: 468-477.
19. Patrono C, García Rodríguez LA, Landolfi R, et al. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353: 2373-2383.
20. Pratt S, Thompson VJ, Elkin EP, et al. The impact of upper gastrointestinal symptoms on nonadherence to, and discontinuation of, low-dose acetylsalicylic acid in patients with cardiovascular risk. Am J Cardiovasc Drugs 2010; 10: 281-288.
21. Moberg C, Naesdal J, Svedberg L-E, et al. Impact of gastrointestinal problems on adherence to low-dose acetylsalicylic acid: a quantitative study in patients with cardiovascular risk. Patient 2011; 4: 103-113.
22. Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. Circulation 2010; 122: 2619-2633.
23. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. Circulation 2008; 118: 1894-1909.
24. van Haalen HGM, De Groot NL, Focks JJ, et al. All low dose aspirin users benefit from gastroprotection: results of a cost-utility analysis of competing strategies. Gut 2011; 60 (Suppl 3): A158.
25. Saini SD, Fendrick AM, Scheiman JM. Cost-effectiveness analysis: cardiovascular benefits of proton pump inhibitor co-therapy in patients using aspirin for secondary prevention. Aliment Pharmacol Ther 2011; 34: 243-251.
26. Moukarbel GV, Bhatt DL. Antiplatelet therapy and proton pump inhibition: clinician update. Circulation 2012; 125: 375-380.
27. Martín-Merino E, Johansson S, Nagy P, et al. Effect of Baseline Gastrointestinal Risk and Use of Proton Pump Inhibitors on Frequency of Discontinuation of Aspirin for Secondary Cardiovascular Prevention in United Kingdom Primary Care. Am J Cardiol 2013; doi: 10. 1016/j. amjcard. 2013. 05. 051. [Epub ahead of print].
28. Sud A, Kline-Rogers EM, Eagle KA, et al. Adherence to medications by patients after acute coronary syndromes. Ann Pharmacother 2005; 39: 1792-1797.
29. Burger W, Chemnitius JM, Kneissl GD, et al. Low-dose aspirin for secondary cardiovascular prevention-cardiovascular risks after its perioperative withdrawal versus bleeding risks with its continuation-review and meta-analysis. J Intern Med 2005; 257: 399-414.
30. Bedson J, Whitehurst T, Lewis M, et al. Factors affecting over-the-counter use of aspirin in the secondary prophylaxis of cardiovascular disease. Br J Gen Pract 2001; 51: 1001-1003.
31. Campbell NC, Thain J, Deans HG, et al. Secondary prevention in coronary heart disease: baseline survey of provision in general practice. Br Med J 1998; 316: 1430-1434.
32. Hopper S, Pierce M. Aspirin after myocardial infarction: the importance of over-the-counter use. Fam Pract 1998; 15 (Suppl 1): S10-13.
33. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-1762.
34. de Gaetano G. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Collaborative Group of the Primary Prevention Project. Lancet 2001; 357: 89-95.
35. Ridker PM, Cook NR, Lee IM, et al. A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med 2005; 352: 1293-1304.
36. Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998; 351: 233-241.
37. He J, Whelton PK, Vu B, et al. Aspirin and risk of hemorrhagic stroke: a metaanalysis of randomized controlled trials. J Am Med Assoc 1998; 280: 1930-1935.
38. Rist PM, Buring JE, Kase CS, et al. Effect of low-dose aspirin on functional outcome from cerebral vascular events in women. Stroke 2013; 44: 432-436.